Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 5,375 | 843 | 4,487 |
| Samples | 3,255 | 590 | 2,638 |
| Peptides | 3,124 | 484 | 2,729 |
Function
MUC17 · Mucin 17, cell surface associated
The protein encoded by this gene is a membrane-bound mucin that provides protection to gut epithelial cells. The encoded protein contains about 60 tandem repeats, with each repeat being around 60 aa. N-glycosylation enables the encoded protein to localize on the cell surface, while the C-terminus interacts with the scaffold protein PDZ domain containing 1 (PDZK1). Two transcript variants, one protein-coding and the other non-protein coding, have been found for this gene. [provided by RefSeq, Nov 2015].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 2500 amino-acid changes on canonical ENST00000306151 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in MUC17 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in MUC17 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Melanoma | 51/210 24% | 416/1899 22% |
| Glioblastoma | 17/98 17% | 0/0 0% |
| Non-Small Cell Lung Carcinoma | 72/304 24% | 209/1390 15% |
| Chronic Myelogenous Leukemia | 4/25 16% | 0/0 0% |
| T-Lymphoblastic Leukemia | 6/40 15% | 0/0 0% |
| Endometrial Carcinoma | 14/42 33% | 79/612 13% |
| Squamous Cell Lung Carcinoma | 9/57 16% | 112/810 14% |
| Small Cell Lung Carcinoma | 2/9 22% | 86/752 11% |
| Oral Cavity Carcinoma | 6/54 11% | 0/0 0% |
| Hodgkins Lymphoma | 4/16 25% | 11/122 9% |
| Colorectal Carcinoma | 37/143 26% | 307/3239 9% |
| Other Solid Cancers | 10/94 11% | 140/1515 9% |
| Bladder Carcinoma | 11/58 19% | 81/956 8% |
| Acute Myeloid Leukemia | 8/90 9% | 0/0 0% |
| Cervical Carcinoma | 4/35 11% | 36/422 9% |
| Neuroendocrine Tumour | 41/154 27% | 22/577 4% |
| Gastric Carcinoma | 21/74 28% | 134/1809 7% |
| Plasma Cell Myeloma | 9/44 20% | 13/305 4% |
| Esophageal Carcinoma | 5/23 22% | 42/769 5% |
| Hepatocellular Carcinoma | 13/46 28% | 119/2210 5% |
| Chondrosarcoma | 0/14 0% | 5/75 7% |
| Head and Neck Carcinoma | 17/85 20% | 74/1574 5% |
| Ovarian Carcinoma | 20/109 18% | 40/998 4% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 7/133 5% |
| Germ Cell Tumour | 1/25 4% | 9/169 5% |
| Thymic Epithelial Tumor | 0/0 0% | 2/39 5% |
| Chordoma | 0/7 0% | 1/13 8% |
| Other Sarcomas | 12/69 17% | 25/699 4% |
| Osteosarcoma | 6/45 13% | 4/166 2% |
| Glioma | 8/52 15% | 90/2127 4% |
Mutation Distribution
Where MUC17 is mutated · all tissues, split by cell line vs tissue
How many mutations in MUC17 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 41 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 5,375 mutations in MUC17
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|